feed,title,long_url,short_url
Benzinga,NKX101's Leukemia Setting Phase 1 Results a Setback for Nkarta: Analyst Lowers Price Target Amid Revised Development Timeline,https://benzinga.com/news/23/06/33031161/nkx101s-leukemia-setting-phase-1-results-a-setback-for-nkarta-analyst-lowers-price-target-amid-revis,https://da.gd/Lf8mAn
Benzinga,"Analyst Downgrades Adicet Citing Uncertainty, Awaits Long-Term Data On Durability",https://benzinga.com/general/biotech/23/06/33030757/analyst-downgrades-adicet-citing-uncertainty-awaits-long-term-data-on-durability,https://da.gd/INlIyq
